Literature DB >> 3783276

Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method.

H J Haisma, J Hilgers, V R Zurawski.   

Abstract

We have developed a convenient system that can be used to iodinate monoclonal antibodies for diagnosis or therapy. A vial, previously coated with 1,3,4,6-tetrachloro-3a, 6a-diphenyl glycouril (iodogen), is used as a reaction vessel. Iodination and separation of bound and free iodide, using AG1-X8 ion exchange resin, are both accomplished in this vial. We found 90 +/- 4% of the iodide which was added was incorporated, respectively, into each of four different monoclonal antibodies evaluated. Approximately 90% of labeled antibody was recovered in each case. The monoclonal antibody OC125 was labeled to specific activities up to 25 mCi/mg. Immunoreactivities of 82 +/- 2% using 125I and 66 +/- 5% using 131I were achieved. As the radioiodination is done in one sealed vial and takes less than 15 min, this procedure is safe and can be performed in any nuclear medicine laboratory. The final product, which is sterile and apyrogenic, is suitable for diagnostic and radiotherapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783276

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  A monoclonal antibody specific for cells of the melanocyte lineage.

Authors:  C Vennegoor; P Hageman; H Van Nouhuijs; D J Ruiter; J Calafat; P J Ringens; P Rümke
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

2.  Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man.

Authors:  H J Haisma; M A Kessel; C Silva; M van Muijen; J C Roos; H Bril; H J Martens; R McCabe; E Boven
Journal:  Br J Cancer Suppl       Date:  1990-07

3.  Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.

Authors:  H J Haisma; E Boven; M van Muijen; R De Vries; H M Pinedo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia.

Authors:  J J Quak; A J Balm; G A van Dongen; J G Brakkee; R J Scheper; G B Snow; C J Meijer
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

5.  Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984.

Authors:  A H Schrijvers; M Gerretsen; M van Walsum; B J Braakhuis; J J Quak; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian-cancer-bearing nude mice.

Authors:  C F Molthoff; H M Pinedo; H M Schlüper; E Boven
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb.

Authors:  Catherine A Foss; Liudmila Kulik; Alvaro A Ordonez; Sanjay K Jain; V Michael Holers; Joshua M Thurman; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

8.  Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.

Authors:  C F Molthoff; H M Pinedo; H M Schlüper; H W Nijman; E Boven
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

9.  Involvement of leukocyte function-associated antigen-1 (LFA-1) in the invasion of hepatocyte cultures by lymphoma and T-cell hybridoma cells.

Authors:  E Roos; F F Roossien
Journal:  J Cell Biol       Date:  1987-07       Impact factor: 10.539

10.  A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.

Authors:  H J Haisma; E Boven; M van Muijen; J de Jong; W J van der Vijgh; H M Pinedo
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.